Sarepta Therapeutics traded at $77.07 this Wednesday June 29th, increasing $2.40 or 3.21 percent since the previous trading session. Looking back, over the last four weeks, Sarepta Therapeutics gained 5.84 percent. Over the last 12 months, its price fell by 0.86 percent. Looking ahead, we forecast Sarepta Therapeutics to be priced at 73.20 by the end of this quarter and at 67.45 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 3,437.00 40.00 1.18% 43.54%
Acadia Pharmaceuticals 14.22 0.22 1.57% -41.70%
Agios Pharmaceuticals 22.38 -0.23 -1.02% -59.39%
Alnylam Pharmaceuticals 145.43 3.23 2.27% -14.21%
Amgen 245.43 1.92 0.79% 0.69%
Avrobio Inc 1.01 0.05 4.79% -88.64%
BioCryst Pharmaceuticals 10.81 0.35 3.35% -31.63%
Biogen 205.23 2.72 1.34% -40.73%
Bluebird Bio 4.58 0.54 13.37% -85.68%
BioMarin Pharmaceutical 83.92 0.77 0.93% 0.58%
Capricor Therapeutics 3.76 -0.11 -2.84% -26.71%
Esperion Therapeutics 6.67 0.40 6.38% -68.46%
Gilead Sciences 62.48 0.27 0.43% -9.27%
Intercept Pharmaceuticals 13.67 0.67 5.15% -31.55%
Incyte Corp 75.89 0.26 0.34% -9.79%
Insmed 20.07 0.16 0.80% -29.48%
Ionis Pharmaceuticals 37.56 -0.41 -1.08% -5.84%
Eli Lilly 323.00 5.38 1.69% 40.73%
Moderna Inc 142.81 0.62 0.44% -39.22%
Mirati Therapeutics 67.24 -1.26 -1.84% -58.37%
Neurocrine Biosciences 98.46 1.53 1.58% 1.17%
Nektar Therapeutics 3.96 -0.06 -1.49% -76.92%
Lumos Pharma Inc. 7.71 0.07 0.92% -22.90%
Novavax 51.85 0.79 1.55% -75.58%
Pfizer 50.94 0.28 0.55% 30.08%
PTC Therapeutics 40.40 0.46 1.15% -4.42%
Ultragenyx Pharmaceutical 60.24 1.51 2.57% -36.82%
Regeneron Pharmaceuticals 597.62 3.20 0.54% 4.00%
Roche Holding 319.65 2.10 0.66% -8.29%
Sanofi 97.70 -3.18 -3.15% 10.57%
Sangamo BioSciences 4.14 0.05 1.22% -65.41%
Sarepta Therapeutics 77.07 2.40 3.21% -0.86%
Vertex Pharmaceuticals 280.35 4.18 1.51% 38.64%

Indexes Price Day Year
USND 11178 -3.65 -0.03% -22.93%
US2000 1719 -19.47 -1.12% -25.59%

Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. Its commercial products, EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection is for the treatment of DMD in patients, who have a confirmed mutation of the DMD gene that is amenable to exon 51, exon 53 and exon 45 skipping. It is also developing gene therapy programs for various forms of LGMDs. Its LGMD product candidate, SRP-9003, is designed to transfer a gene that codes for and restores beta-sarcoglycan protein.